A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell-derived allogeneic cell therapies.

Dashnau, Jennifer L; Xue, Qiong; Nelson, Monica; Law, Eric; Cao, Lan; Hei, Derek

Dashnau, Jennifer L; Xue, Qiong; Nelson, Monica; Law, Eric; Cao, Lan; Hei, Derek.

Afiliação

Dashnau JL; Century Therapeutics, Inc., Philadelphia, Pennsylvania, USA. Electronic address: jdashnau@centurytx.com.
Xue Q; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Nelson M; Century Therapeutics, Inc., Philadelphia, Pennsylvania, USA.
Law E; Century Therapeutics, Inc., Philadelphia, Pennsylvania, USA.
Cao L; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Hei D; Clade Therapeutics, One Kendall Square, Cambridge, Massachusetts, USA.

Cytotherapy ; 25(1): 1-13, 2023 01.

Article em En | MEDLINE | ID: mdl-36109321

Assuntos

Células-Tronco Pluripotentes Induzidas; Células-Tronco Pluripotentes Induzidas/metabolismo; Células Alógenas; Diferenciação Celular; Reprogramação Celular; Linhagem Celular

Palavras-chave

Allogeneic; Cell banking; Cell therapy; Critical components; Donor eligibility; Genetic stability; Induced pluripotent stem cells (iPSCs); Raw materials; Regulatory guidelines

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Cytotherapy Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google